Healthcare Industry News: Ventana
News Release - March 3, 2009
BioImagene Appoints Douglas Sweet as Vice President of Sales and MarketingCUPERTINO, Calif.--(HSMN NewsFeed)--BioImagene, the leading provider of innovative digital pathology solutions, today announced the appointment of Doug Sweet as Vice President of Sales and Marketing. Mr. Sweet has more than 30 years of experience in business development, marketing and sales in the Diagnostic Industry – Clinical and Anatomic Pathology, Life Science and BioPharma.
Dr. Ajit Singh, CEO BioImagene commented, “We are extremely pleased that Doug has joined the BioImagene team. As the pathology industry transitions into a digital era, Doug’s experience will be a valuable asset in further strengthening our market leadership. His proven success in launching over a dozen diagnostic products in his career will help us as we roll out the industry’s most comprehensive line of digital pathology solutions.”
For the last three years, Doug served as Vice President of Marketing and Sales for Celerus Diagnostics where he created a Sales, Marketing and Customer Care team to launch a revolutionary IHC system. Prior to joining Celerus, Doug has held various executive positions in Business Development and Sales/Marketing at Ventana Medical Systems, Dako Corporation, BioPath Corporation, Molecular Devices, as well as Syva, an early stage division of Syntex Corporation. Doug has also worked at New England Nuclear and Corning Medical and served as an advisor for Agilent Technologies, Exagen Diagnostics, HistoRx, BioImagene, Pathworks Diagnostics and Spring BioSystems.
“I am privileged to be joining BioImagene, at this point in the company’s evolution. The company is poised for tremendous growth with their unique solutions and business model,” commented Mr. Sweet.
Mr. Sweet holds a BS in Biology from the University of Oregon and an MBA from the Presidential/Key Executive program at Pepperdine University.
BioImagene (www.bioimagene.com) is the leader in providing innovative and affordable digital pathology solutions for clinical diagnostics and drug discovery. BioImagene products are FDA-cleared for specific clinical applications and are intended for research use for other applications.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.